These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423 [Abstract] [Full Text] [Related]
15. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T. J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663 [Abstract] [Full Text] [Related]
19. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, Nemoto K, Kondo T. Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161 [Abstract] [Full Text] [Related]